Pim kinases in cancer: Diagnostic, prognostic and treatment opportunities

被引：151

作者：

Blanco-Aparicio, Carmen ^{[1
]}

Carnero, Amancio ^{[2
,3
]}

机构：

[1] Spanish Natl Canc Res Ctr, Expt Therapeut Programme, Madrid, Spain

[2] Univ Seville, CSIC, HUVR, Inst Biomed Sevilla IBiS, Seville, Spain

[3] CSIC, Madrid, Spain

来源：

BIOCHEMICAL PHARMACOLOGY | 2013年 / 85卷 / 05期

关键词：

Pim kinases; Cancer targets; Therapeutics; PIM inhibitors; Oncogenes; CHRONIC LYMPHOCYTIC-LEUKEMIA; SMALL-MOLECULE INHIBITOR; HEPATOCELLULAR-CARCINOMA DEVELOPMENT; PROVIRAL INSERTION SITE; CELL-CYCLE ARREST; PROTEIN-KINASE; TRANSGENIC MICE; C-MYC; MITOCHONDRIAL DYSFUNCTION; SERINE/THREONINE KINASES;

D O I：

10.1016/j.bcp.2012.09.018

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

PIM proteins belong to a family of ser/thr kinases composed of 3 members, PIM1, PIM2 and PIM3, with greatly overlapping functions. PIM kinases are mainly responsible for cell cycle regulation, antiapoptotic activity and the homing and migration of receptor tyrosine kinases mediated via the JAK/STAT pathway. PIM kinases have been found to be upregulated in many hematological malignancies and solid tumors. Although these kinases have been described as weak oncogenes, they are heavily targeted for anticancer drug discovery. The present review summarizes the discoveries made to date regarding PIM kinases as driving oncogenes in the process of tumorigenesis and their validation as drug targets. (C) 2012 Elsevier Inc. All rights reserved.

引用

页码：629 / 643

页数：15

共 156 条

[1]

Acton D, 1992, Curr Top Microbiol Immunol, V182, P293

[2]

Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL [J].

Adam, M ;

Pogacic, V ;

Bendit, M ;

Chappuis, R ;

Nawijn, MC ;

Duyster, J ;

Fox, CJ ;

Thompson, CB ;

Cools, J ;

Schwaller, J .

CANCER RESEARCH, 2006, 66 (07) :3828-3835

[3]

Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation [J].

Agrawal, S. ;

Koschmieder, S. ;

Baeumer, N. ;

Reddy, N. G. P. ;

Berdel, W. E. ;

Mueller-Tidow, C. ;

Serve, H. .

LEUKEMIA, 2008, 22 (01) :78-86

[4]

Pim-1 kinase phosphorylates RUNX family transcription factors and enhances their activity [J].

Aho, Teija L. T. ;

Sandholm, Jouko ;

Peltola, Katriina J. ;

Ito, Yoshiaki ;

Koskinen, Paivi J. .

BMC CELL BIOLOGY, 2006, 7 (1)

[5]

Synthesis, Kinase Inhibitory Potencies, and in Vitro Antiproliferative Evaluation of New Pim Kinase Inhibitors [J].

Akue-Gedu, Rufine ;

Rossignol, Emilie ;

Azzaro, Stephane ;

Knapp, Stefan ;

Filippakopoulos, Panagis ;

Bullock, Alex N. ;

Bain, Jenny ;

Cohen, Philip ;

Prudhomme, Michelle ;

Anizon, Fabrice ;

Moreau, Pascale .

JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (20) :6369-6381

[6]

Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc [J].

Allen, JD ;

Verhoeven, E ;

Domen, J ;

vanderValk, M ;

Berns, A .

ONCOGENE, 1997, 15 (10) :1133-1141

[7]

The survival kinases Akt and Pim as potential pharmacological targets [J].

Amaravadi, R ;

Thompson, CB .

JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (10) :2618-2624

[8]

The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C [J].

Bachmann, M ;

Kosan, C ;

Xing, PX ;

Montenarh, M ;

Hoffmann, I ;

Möröy, T .

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2006, 38 (03) :430-443

[9]

The serine/threonine kinase pim-1 [J].

Bachmann, M ;

Möröy, T .

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2005, 37 (04) :726-730

[10]

The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1) -: A novel role for Pim-1 at the G2/M cell cycle checkpoint [J].

Bachmann, M ;

Hennemann, H ;

Xing, PX ;

Hoffmann, I ;

Möröy, T .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (46) :48319-48328

← 1 2 3 4 5 6 7 8 9 10 →